230 related articles for article (PubMed ID: 21586752)
21. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects.
Tuveson DA; Shaw AT; Willis NA; Silver DP; Jackson EL; Chang S; Mercer KL; Grochow R; Hock H; Crowley D; Hingorani SR; Zaks T; King C; Jacobetz MA; Wang L; Bronson RT; Orkin SH; DePinho RA; Jacks T
Cancer Cell; 2004 Apr; 5(4):375-87. PubMed ID: 15093544
[TBL] [Abstract][Full Text] [Related]
22. Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice.
Staffas A; Karlsson C; Persson M; Palmqvist L; Bergo MO
Leukemia; 2015 May; 29(5):1032-40. PubMed ID: 25371176
[TBL] [Abstract][Full Text] [Related]
23. Cooperation of Dnmt3a R878H with Nras G12D promotes leukemogenesis in knock-in mice: a pilot study.
Shi X; Yang Y; Shang S; Wu S; Zhang W; Peng L; Huang T; Zhang R; Ren R; Mi J; Wang Y
BMC Cancer; 2019 Nov; 19(1):1072. PubMed ID: 31703632
[TBL] [Abstract][Full Text] [Related]
24. Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis.
Kong G; Chang YI; Damnernsawad A; You X; Du J; Ranheim EA; Lee W; Ryu MJ; Zhou Y; Xing Y; Chang Q; Burd CE; Zhang J
Leukemia; 2016 Jul; 30(7):1542-51. PubMed ID: 27055865
[TBL] [Abstract][Full Text] [Related]
25. Palmitoylation of oncogenic NRAS is essential for leukemogenesis.
Cuiffo B; Ren R
Blood; 2010 Apr; 115(17):3598-605. PubMed ID: 20200357
[TBL] [Abstract][Full Text] [Related]
26. Somatic mosaicism for oncogenic NRAS mutations in juvenile myelomonocytic leukemia.
Doisaki S; Muramatsu H; Shimada A; Takahashi Y; Mori-Ezaki M; Sato M; Kawaguchi H; Kinoshita A; Sotomatsu M; Hayashi Y; Furukawa-Hibi Y; Yamada K; Hoshino H; Kiyoi H; Yoshida N; Sakaguchi H; Narita A; Wang X; Ismael O; Xu Y; Nishio N; Tanaka M; Hama A; Koike K; Kojima S
Blood; 2012 Aug; 120(7):1485-8. PubMed ID: 22753870
[TBL] [Abstract][Full Text] [Related]
27. Preclinical efficacy of MEK inhibition in Nras-mutant AML.
Burgess MR; Hwang E; Firestone AJ; Huang T; Xu J; Zuber J; Bohin N; Wen T; Kogan SC; Haigis KM; Sampath D; Lowe S; Shannon K; Li Q
Blood; 2014 Dec; 124(26):3947-55. PubMed ID: 25361812
[TBL] [Abstract][Full Text] [Related]
28. Oncogenic NRAS hyper-activates multiple pathways in human cord blood stem/progenitor cells and promotes myelomonocytic proliferation in vivo.
Wang T; Li C; Xia C; Dong Y; Yang D; Geng Y; Cai J; Zhang J; Zhang X; Wang J
Am J Transl Res; 2015; 7(10):1963-73. PubMed ID: 26692939
[TBL] [Abstract][Full Text] [Related]
29. K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.
Kindler T; Cornejo MG; Scholl C; Liu J; Leeman DS; Haydu JE; Fröhling S; Lee BH; Gilliland DG
Blood; 2008 Oct; 112(8):3373-82. PubMed ID: 18663146
[TBL] [Abstract][Full Text] [Related]
30. Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras.
Xu J; Hedberg C; Dekker FJ; Li Q; Haigis KM; Hwang E; Waldmann H; Shannon K
Blood; 2012 Jan; 119(4):1032-5. PubMed ID: 22144181
[TBL] [Abstract][Full Text] [Related]
31. Mouse model for NRAS-induced leukemogenesis.
Parikh C; Ren R
Methods Enzymol; 2008; 439():15-24. PubMed ID: 18374153
[TBL] [Abstract][Full Text] [Related]
32. Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner.
Gilad O; Nabet BY; Ragland RL; Schoppy DW; Smith KD; Durham AC; Brown EJ
Cancer Res; 2010 Dec; 70(23):9693-702. PubMed ID: 21098704
[TBL] [Abstract][Full Text] [Related]
33. KRAS (G12D) cooperates with AML1/ETO to initiate a mouse model mimicking human acute myeloid leukemia.
Zhao S; Zhang Y; Sha K; Tang Q; Yang X; Yu C; Liu Z; Sun W; Cai L; Xu C; Cui S
Cell Physiol Biochem; 2014; 33(1):78-87. PubMed ID: 24480914
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation.
Zhang J; Wang J; Liu Y; Sidik H; Young KH; Lodish HF; Fleming MD
Blood; 2009 Feb; 113(6):1304-14. PubMed ID: 19066392
[TBL] [Abstract][Full Text] [Related]
35. N-Ras(G12D) induces features of stepwise transformation in preleukemic human umbilical cord blood cultures expressing the AML1-ETO fusion gene.
Chou FS; Wunderlich M; Griesinger A; Mulloy JC
Blood; 2011 Feb; 117(7):2237-40. PubMed ID: 21200020
[TBL] [Abstract][Full Text] [Related]
36. Oncogenic cooperation between TCF7-SPI1 and NRAS(G12D) requires β-catenin activity to drive T-cell acute lymphoblastic leukemia.
Van Thillo Q; De Bie J; Seneviratne JA; Demeyer S; Omari S; Balachandran A; Zhai V; Tam WL; Sweron B; Geerdens E; Gielen O; Provost S; Segers H; Boeckx N; Marshall GM; Cheung BB; Isobe K; Kato I; Takita J; Amos TG; Deveson IW; McCalmont H; Lock RB; Oxley EP; Garwood MM; Dickins RA; Uyttebroeck A; Carter DR; Cools J; de Bock CE
Nat Commun; 2021 Jul; 12(1):4164. PubMed ID: 34230493
[TBL] [Abstract][Full Text] [Related]
37. Temporal dissection of K-ras(G12D) mutant in vitro and in vivo using a regulatable K-ras(G12D) mouse allele.
Wang Z; Feng Y; Bardeesy N; Wong KK; Liu XY; Ji H
PLoS One; 2012; 7(5):e37308. PubMed ID: 22606359
[TBL] [Abstract][Full Text] [Related]
38. The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia.
Shi J; Wang E; Zuber J; Rappaport A; Taylor M; Johns C; Lowe SW; Vakoc CR
Oncogene; 2013 Feb; 32(7):930-8. PubMed ID: 22469984
[TBL] [Abstract][Full Text] [Related]
39. Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity.
Kunimoto H; Meydan C; Nazir A; Whitfield J; Shank K; Rapaport F; Maher R; Pronier E; Meyer SC; Garrett-Bakelman FE; Tallman M; Melnick A; Levine RL; Shih AH
Cancer Cell; 2018 Jan; 33(1):44-59.e8. PubMed ID: 29275866
[TBL] [Abstract][Full Text] [Related]
40. Embryonic Expression of Nras
You X; Ryu MJ; Cho E; Sang Y; Damnernsawad A; Zhou Y; Liu Y; Zhang J; Lee Y
Front Cell Dev Biol; 2021; 9():633661. PubMed ID: 33681212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
